MecRx

MecRx is an early stage drug development company working on new treatments for cancer and novel mechanism of action antibiotics. Using proprietary “hit identification” technology, MecRx is developing inhibitors of cMyc, a protein that is deregulated in over 50% of all human cancers. MecRx draws on the expertise of the Peter MacCallum Cancer Centre and CSIRO and is headquartered in Melbourne, Australia.

www.mecrx.com

Back to List